Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Esophageal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Neuroendocrine 1Anophthalmia with pulmonary hypoplasia 1

Interventions

Biopsy 5X-Rays 4Specimen Handling 4Phantoms, Imaging 4Nuclear Medicine Department, Hospital 4Magnetic Resonance Spectroscopy 4Carboplatin 3larotrectinib 2erdafitinib 2ensartinib 2cabozantinib 2Topotecan 2Temozolomide 2Etoposide 2Cyclophosphamide 2Cisplatin 2ulixertinib 1tipifarnib 1tazemetostat 1selpercatinib 1pegfilgrastim 1palbociclib 1olaparib 1niraparib 1mirdametinib 1ivosidenib 1irinotecan sucrosofate 1entrectinib 1elacestrant 1budigalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × budigalimab × 30 days × Clear all
NCT05599984 2026-05-07

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

AbbVie

Phase 1 Active not recruiting
288 enrolled
CNSEndocrineThoracic

Neoplasms, Central Nervous System Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡